What are the benefits of using NOACs over VKA for stroke prevention in patients with AF?
NOACs (Novel Oral Anticoagulants) have been found to be more effective than VKA (Vitamin K Antagonists) for stroke prevention in patients with AF (Atrial Fibrillation). Studies have found that NOACs are associated with lower rates of stroke, systemic embolism, and death compared with VKA. Additionally, NOACs are associated with lower rates of major bleeding, including intracranial hemorrhage, compared with VKA. NOACs also have the benefit of having fewer drug and food interactions than VKA and require less frequent monitoring than VKA. 